CA2239308A1 - New combination - Google Patents

New combination Download PDF

Info

Publication number
CA2239308A1
CA2239308A1 CA002239308A CA2239308A CA2239308A1 CA 2239308 A1 CA2239308 A1 CA 2239308A1 CA 002239308 A CA002239308 A CA 002239308A CA 2239308 A CA2239308 A CA 2239308A CA 2239308 A1 CA2239308 A1 CA 2239308A1
Authority
CA
Canada
Prior art keywords
active ingredient
solvate
formoterol
budesonide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002239308A
Other languages
English (en)
French (fr)
Inventor
Anders Ullman
Jan Trofast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2239308A1 publication Critical patent/CA2239308A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
CA002239308A 1996-10-08 1997-09-24 New combination Abandoned CA2239308A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9603669A SE9603669D0 (sv) 1996-10-08 1996-10-08 New combination
SE9603669-4 1996-10-08

Publications (1)

Publication Number Publication Date
CA2239308A1 true CA2239308A1 (en) 1998-04-16

Family

ID=20404167

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002239308A Abandoned CA2239308A1 (en) 1996-10-08 1997-09-24 New combination

Country Status (18)

Country Link
EP (1) EP0871450A1 (ja)
JP (1) JP2000502365A (ja)
KR (1) KR19990071975A (ja)
AR (1) AR013614A1 (ja)
AU (1) AU715319B2 (ja)
BR (1) BR9706822A (ja)
CA (1) CA2239308A1 (ja)
CZ (1) CZ176198A3 (ja)
HU (1) HUP9901674A3 (ja)
MY (1) MY128337A (ja)
NO (1) NO982414D0 (ja)
NZ (1) NZ330482A (ja)
PL (1) PL327037A1 (ja)
SE (1) SE9603669D0 (ja)
SK (1) SK75198A3 (ja)
TW (1) TW470647B (ja)
WO (1) WO1998015280A1 (ja)
ZA (1) ZA978889B (ja)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9700136D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US5980949A (en) * 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
SE9700134D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
SE9700135D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
WO1999000134A1 (en) * 1997-06-27 1999-01-07 Astra Aktiebolag (Publ) New combination of antiasthma medicaments
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
SE9900834D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
IN2014MN00380A (ja) 2006-06-30 2015-06-19 Iceutica Pty Ltd
EP2327403A3 (en) 2007-02-19 2011-08-31 Cipla Limited Pharmaceutical combinations of at least two bronchodilators
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
TWI695723B (zh) 2009-05-29 2020-06-11 美商沛爾醫療股份有限公司 用於經由呼吸道輸送活性劑的組成物以及相關方法與系統
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
AU2013227351B2 (en) * 2012-02-28 2016-06-16 Iceutica Holdings Inc. Inhalable pharmaceutical compositions
ITMI20130571A1 (it) 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69232462T2 (de) * 1991-12-18 2002-10-10 Astrazeneca Ab Formoterol und budesonide enthaltende zusammensetzung

Also Published As

Publication number Publication date
CZ176198A3 (cs) 1998-09-16
TW470647B (en) 2002-01-01
AR013614A1 (es) 2001-01-10
NZ330482A (en) 1999-11-29
HUP9901674A2 (hu) 1999-09-28
SE9603669D0 (sv) 1996-10-08
KR19990071975A (ko) 1999-09-27
ZA978889B (en) 1998-04-08
PL327037A1 (en) 1998-11-09
AU4578297A (en) 1998-05-05
WO1998015280A1 (en) 1998-04-16
BR9706822A (pt) 1999-03-23
AU715319B2 (en) 2000-01-20
JP2000502365A (ja) 2000-02-29
HUP9901674A3 (en) 2001-04-28
SK75198A3 (en) 1998-11-04
MY128337A (en) 2007-01-31
EP0871450A1 (en) 1998-10-21
NO982414L (no) 1998-05-27
NO982414D0 (no) 1998-05-27

Similar Documents

Publication Publication Date Title
CA2239308A1 (en) New combination
US8461211B2 (en) Use for budesonide and formoterol
AU673660B2 (en) New combination of formoterol and budesonide
EP1480615B1 (en) Formoterol superfine formulation
JP3042867B2 (ja) 呼吸疾患治療薬
EP1085877B1 (en) Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
EP1834643A2 (en) Novel medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
JP3042866B2 (ja) 呼吸疾患治療薬
WO2000053187A1 (en) New combination of formoterol and mometasone in a pharmaceutical composition for treating respiratory disorders, such as asthma, rhinitis and copd
WO1999000134A1 (en) New combination of antiasthma medicaments
MXPA98004357A (en) New combination
MXPA99011676A (en) New combination of antiasthma medicaments

Legal Events

Date Code Title Description
FZDE Discontinued